Solana Company (HSDT) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
30 Apr, 2026Executive summary
Completed a transformative year, expanding from a passive holding structure to a multifaceted platform with capital markets, asset management, and marketing/partnership activities.
Achieved $5.2 million in Q4 2025 revenue, up from $0.2 million year-over-year, driven by staking rewards.
Closed a $500+ million PIPE transaction in September 2025, marking a new strategic phase.
Reported Q4 net income of $325.6 million, reversing a net loss of $3.9 million in the prior-year quarter, due to a significant gain from derivative liability revaluation.
Expanded business through digital asset treasury, share repurchases, and strategic partnerships.
Financial highlights
Q4 2025 revenue was $5.2 million, with $5.1 million from staking; full year 2025 revenue was $6 million, up from $0.5 million in 2024.
Q4 2025 operating expenses were $206.1 million, including $178.3 million in unrealized losses on digital assets.
Q4 2025 net income was $325.6 million, driven by a $526.3 million gain from derivative liability revaluation; full year 2025 net loss was $40.9 million.
Ended 2025 with $7.3 million in cash and $293.7 million in digital assets; total cash and digital assets at fair value were $301.0 million.
Q4 EPS was $4.25; full year EPS was a loss of $1.85.
Outlook and guidance
Plans to activate Pacific Backbone nodes in Asia-Pacific, optimize performance, and launch liquidity-related products within 12–18 months.
Continues to focus on long-term SOL accumulation and enhancing SOL per share metrics.
Evaluating capital formation alternatives, including convertible debt, warrant-linked structures, and strategic M&A.
Anticipates further yield enhancement from the Anchorage/Kamino partnership.
Management remains committed to sustainable growth despite adverse crypto market and macroeconomic headwinds.
Latest events from Solana Company
- Shareholders will vote on director elections, auditor ratification, and board changes at the virtual annual meeting.HSDT
Proxy filing1 May 2026 - Annual meeting to elect directors, ratify auditor, and reinforce governance and sustainability.HSDT
Proxy filing10 Apr 2026 - First third-party reimbursement and Medicare rates expected to drive late-2024 revenue growth.HSDT
Q2 20241 Feb 2026 - CMS pricing delays hinder access and commercialization, prompting strategic review and regulatory focus.HSDT
Status Update13 Jan 2026 - 6.2 million shares registered for resale after warrant exercises; no proceeds to the company.HSDT
Registration Filing16 Dec 2025 - Registering 6.2M shares for resale after $3.7M in warrant exercises, amid Nasdaq compliance risks.HSDT
Registration Filing16 Dec 2025 - Annual meeting seeks approval for director elections, warrant issuance, and a reverse stock split.HSDT
Proxy Filing2 Dec 2025 - Shareholders will vote on director election, warrant issuances, and expanding the equity plan.HSDT
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, warrant shares, and reverse stock split for Nasdaq compliance.HSDT
Proxy Filing2 Dec 2025